PharmaEngine

PharmaEngine ROIC

The Return on Invested Capital (ROIC) of PharmaEngine (4162.TWO) as of Nov 18, 2026 is 7.87 %. In the previous year, Return on Invested Capital (ROIC) was 32.43 % — a change of -75.73% (lower).

ROIC

7.87 %

YoY

-75.73%

Last updated:

Return on Invested Capital (ROIC) of PharmaEngine is 2025 7.87 % . Return on Invested Capital (ROIC) of PharmaEngine was 2024 32.43 % . It decreases by -75.73% lower compared to the previous year.

The PharmaEngine ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
3.50 TWD
Jan 1, 2019
1.21 TWD
Jan 1, 2020
14.98 TWD
Jan 1, 2021
10.80 TWD
Jan 1, 2022
8.19 TWD
Jan 1, 2023
7.08 TWD
Jan 1, 2024
32.43 TWD
Jan 1, 2025
7.87 TWD
The PharmaEngine ROIC history
YEARROICYoY
7.87 %-75.73%
32.43 %+357.84%
7.08 %-13.47%
8.19 %-24.18%
10.80 %-27.94%
14.98 %+1,138.18%
1.21 %-65.43%
3.50 %-64.62%
9.90 %-45.49%
18.15 %+45.72%
12.46 %+195.16%
4.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Return on Invested Capital (ROIC) of PharmaEngine is 7.87 % in 2025.

Return on Invested Capital (ROIC) of PharmaEngine changed from 32.43 % to 7.87 %, representing a -75.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — PharmaEngine

All Key Metrics — PharmaEngine